Gregory Mayhew

Title: Gregory Mayhew: Innovator in Lung Cancer Subtyping

Introduction

Gregory Mayhew is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of molecular diagnostics, particularly in the subtyping of lung cancer. His innovative methods have the potential to improve patient outcomes through more accurate cancer classification.

Latest Patents

Gregory Mayhew holds a patent for "Methods for typing of lung cancer." This patent provides methods and compositions for the molecular subtyping of lung cancer samples. Specifically, it includes a method for assessing whether a patient's lung cancer subtype is adenocarcinoma, squamous cell carcinoma, or neuroendocrine, which encompasses both small cell carcinoma and carcinoid. The methods involve probing the levels of classifier biomarkers at the nucleic acid level in lung cancer samples obtained from patients. Based on these levels, the lung cancer sample can be classified as a particular subtype.

Career Highlights

Throughout his career, Gregory Mayhew has worked with prominent organizations such as Genecentric Therapeutics, Inc. and the University of North Carolina at Chapel Hill. His work has focused on advancing the understanding and treatment of lung cancer through innovative research and development.

Collaborations

Gregory has collaborated with esteemed colleagues, including Myla Lai-Goldman and Hawazin Faruki. These collaborations have contributed to the advancement of research in the field of oncology.

Conclusion

Gregory Mayhew's contributions to lung cancer research through his patented methods exemplify the importance of innovation in medical science. His work not only enhances the understanding of lung cancer subtypes but also paves the way for improved patient care.